Thirty-nine compounds clinics ask about, each with one light and one sentence. Filter by light or topic, then open a row for prescribe, compound, and sell detail plus what to ask your pharmacy.
Loading compounds…
Picked your compounds? See how clinics run them.
The PeptIQ.io provider console does not change a light. It gives you protocol templates, patient logging between visits, adherence per patient, and refill nudges, so the program you can legally offer actually sticks.
Educational reference only, not legal, medical, or regulatory advice. PeptIQ.io does not sell, source, or dispense peptides. Your counsel, your pharmacy, and your state boards decide what applies to your clinic. Verify every source before you rely on it.
Topics
Did the July 2026 PCAC meeting make BPC-157 and TB-500 legal to compound?
No. PCAC advises FDA and its recommendations are non-binding. FDA's own meeting materials proposed not listing either peptide, FDA has posted no decision, and neither is in any 503A category.
Only through a licensed prescriber and a licensed pharmacy, for compounds that pharmacy can lawfully supply, under state scope-of-practice and medical-director rules.
Are compounded GLP-1s the same as Wegovy or Zepbound?
No. Branded products are approved finished drugs; compounded GLP-1s are unapproved preparations with FDA-published concerns about salt forms, dosing errors, and quality.
When staff can state its regulatory status in one clean sentence and a pharmacy letter matches that sentence.
Where do state rules fit if FDA is federal?
Federal compounding pages set the baseline. State pharmacy boards decide licensing, nonresident shipping, and local enforcement; medical boards own supervision and med-spa scope.
What about DSIP after the July 2026 PCAC meeting?
Emideltide (DSIP) is on FDA's safety-risk page as nominated but withdrawn, and FDA's July 24, 2026 PCAC presentation proposed not listing it. Treat it as not a clean menu item.
Because reputation risk, board risk, and supply-chain risk get mashed into one sentence. Separate them and the conversation gets shorter.
Should we use a 503A or 503B pharmacy?
503A is patient-specific compounding; 503B outsourcing facilities make larger batches under different federal oversight, often for office use.
If a peptide is on the 503A Category 1 list, can we compound it tomorrow?
Not automatically. Category 1 means FDA is evaluating the bulk under the interim policy; it is not approval of a finished drug, and pharmacies still decide what they will fill.
Only if a licensed pharmacy will compound under Category 1 conditions and you document a clinical rationale. Wellness marketing is not a federal green light.
Is sermorelin the same clean path as tesamorelin (Egrifta)?
No. Tesamorelin has an approved finished-drug path for labeled lipodystrophy use. Sermorelin is a discontinued-brand / Category 1 compounding question.
What does “essentially a copy” mean for compounded GLP-1s?
When an approved finished drug is commercially available, pharmacies generally cannot compound a copy of it except in narrow shortage or clinically significant difference situations.
The prescribe / compound / sell detail, FDA and board citations, full answers to clinic questions, and the Provider Peptide Field Guide PDF. Work email, free.